Shall we stop or continue angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prior to using contrast agents?

Iranian Journal of Kidney Diseases

Volumn 6, Issue 6, 2012, Pages 397-400

  Ganji, Mohammad Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CONTRAST MEDIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; FENOLDOPAM; FUROSEMIDE; NONIONIC CONTRAST MEDIUM;

ACUTE KIDNEY FAILURE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTRAST INDUCED NEPHROPATHY; CORONARY ARTERY BYPASS GRAFT; CREATININE BLOOD LEVEL; DEATH; DIABETES MELLITUS; DIALYSIS; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HEART DEATH; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOVOLEMIA; KIDNEY DISEASE; KIDNEY FAILURE; MORBIDITY; NEPHROTOXICITY; NONHUMAN; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT;

ACUTE KIDNEY INJURY; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CONTRAST MEDIA; FEMALE; HUMANS; MALE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84869156090     PISSN: 17358582     EISSN: 17358604     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39:930-6.
2. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008;51:1419-28.
3. Toprak O, Cirit M, Bayata S, Yesil M. [Review of the radiocontrast nephropathy risk profiles and risk stratification]. Anadolu Kardiyol Derg. 2004;4:331-5.
4. Kohli HS, Bhaskaran MC, Muthukumar T, et al. Treatment-related acute renal failure in the elderly: a hospital-based prospective study. Nephrol Dial Transplant. 2000;15:212-7.
5. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol. 2000;36:1542-8.
6. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259-64.
7. Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95:13-9.
8. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368-75.
9. Scanlon PJ, Faxon DP, Audet AM, et al. ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol. 1999;33:1756-824.
10. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393-9.
11. Larson TS, Hudson K, Mertz JI, Romero JC, Knox FG. Renal vasoconstrictive response to contrast medium. The role of sodium balance and the renin-angiotensin system. J Lab Clin Med. 1983;101:385-91.
12. Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med. 2004;116:263-72.
13. Fleming I, Kohlstedt K, Busse R. New fACEs to the rennin-angiotensin system. Physiology (Bethesda). 2005;20:91-5.
14. Lee HT, Kim M, Kim J, Kim N, Emala CW. TGF-beta1 release by volatile anesthetics mediates protection against renal proximal tubule cell necrosis. Am J Nephrol. 2007;27:416-24.
15. Spatz C, Saadulla L, Lapsiwala A, Parhizgar A, Ghahramani N. Effect of renin-angiotensin-aldosterone system blockade therapy on incidence of contrast-induced nephropathy in patients with chronic kidney disease. Iran J Kidney Dis. 2012;6:432-6.
16. Toprak O. Angiotensin converting enzyme inhibitors and contrast-induced nephropathy. Ren Fail. 2006;28:99-100.
17. Krusova D, Sevela K, Kralova D, Zak P, Olovska V. [Risky medication and contrast media-induced nephropathy in patients with diabetes and hypertension]. Vnitr Lek. 2006;52:1014-20.
18. Maeder M, Klein M, Fehr T, Rickli H. Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol. 2004;44:1763-71.
19. Cirit M, Toprak O, Yesil M, et al. Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy. Nephron Clin Pract. 2006;104:c20-7.
20. Holscher B, Heitmeyer C, Fobker M, Breithardt G, Schaefer RM, Reinecke H. Predictors for contrast media-induced nephropathy and long-term survival: prospectively assessed data from the randomized controlled Dialysis-Versus-Diuresis (DVD) trial. Can J Cardiol. 2008;24:845-50.
21. Gupta RK, Kapoor A, Tewari S, Sinha N, Sharma RK. Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J. 1999;51:521-6.
22. Rosenstock JL, Bruno R, Kim JK, et al. The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol. 2008;40:749-55.
23. Li X, Li T, Cong H. Is Angiotensin-converting enzyme inhibitor a contraindication for contrast-induced nephropathy prophylaxis? A review about its paradox. Cardiovasc Ther. 2012;30:273-6.
24. Pucelikova T, Dangas G, Mehran R. Contrast-induced nephropathy. Catheter Cardiovasc Interv. 2008;71:62-72.